{"product_id":"masimo-bcg-matrix","title":"Masimo Boston Consulting Group Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSee the Bigger Picture\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eMasimo's BCG Matrix preview shows how its product lines compare by market growth and market share, helping identify which areas may be strong performers in patient monitoring and which newer products may need more attention. Explore the full BCG Matrix for a clear, quadrant-by-quadrant view, simple recommendations, and ready-to-use Word and Excel files to support decisions about investment, R\u0026amp;D, and product priorities.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etars\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHospital Automation and Connectivity Solutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMasimo is rapidly expanding in hospital automation via its Iris platform and connectivity hubs, supporting integrations across 1,200+ hospitals worldwide as of Q4 2025 and contributing to a segment growing ~12% CAGR (2023-2028) per Frost \u0026amp; Sullivan.\u003c\/p\u003e\n\u003cp\u003eAs hospitals push toward fully integrated digital ecosystems to cut clinician burnout, Masimo's high device-integration share (~28% in multi-vendor networks, 2025) positions Iris as a market leader requiring sustained R\u0026amp;D and sales spend.\u003c\/p\u003e\n\u003cp\u003eGiven Masimo's targeted investment-R\u0026amp;D up 18% year-over-year in 2024-these solutions fit the BCG Matrix as Stars: high growth and high share, needing continued capital to secure dominance in the smart hospital market.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced Brain Monitoring and SedLine\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe SedLine brain function monitor is a high-growth product as personalized anesthesia gains traction; global anesthesia device market projected CAGR 6.1% to 2028 supports demand, and Masimo holds an estimated \u0026gt;30% share in OR EEG-derived monitoring niches as of 2025.\u003c\/p\u003e\n\u003cp\u003eClinical studies show SedLine reduces intraoperative awareness risk and shortens PACU time; rising global surgeries (approx 313 million annually in 2015, trending up) mean promotional spend should stay high to protect tech leadership and drive adoption.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eWearable Continuous Monitors and Radius VSM\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRadius VSM and tetherless monitors are Stars in Masimo's BCG matrix, driven by ~18% CAGR in the wireless medical sensor market (2024-30) and hospitals shifting to wireless for workflow gains.\u003c\/p\u003e\n\u003cp\u003eThey enable continuous vitals tracking with patient mobility, reducing ICU dwell times; Masimo reported ~$120M revenue from tetherless devices in FY2024.\u003c\/p\u003e\n\u003cp\u003eMasimo is increasing R\u0026amp;D and sales spend to capture share from wired competitors and target double-digit market share by 2027.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eO3 Regional Oximetry\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eO3 regional oximetry is a high-growth Masimo product measuring tissue oxygenation in brain and organs, capturing ~15-20% market share in regional oximetry by 2024 and growing at ~25% CAGR as hospitals adopt it over pulse oximetry.\u003c\/p\u003e\n\u003cp\u003eAdoption as standard of care in cardiac and neonatal units drives strong revenue potential-Masimo reported global hospital wins adding millions ARR in 2023-yet scaling into new indications needs substantial cash for R\u0026amp;D, sales, and regulatory work.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh growth: ~25% CAGR (2021-24)\u003c\/li\u003e\n\u003cli\u003eMarket share: ~15-20% (2024)\u003c\/li\u003e\n\u003cli\u003eKey markets: cardiac, neonatal units\u003c\/li\u003e\n\u003cli\u003eFunding need: significant capex\/R\u0026amp;D for expansion\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMasimo Freedom Medical Smartwatch\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eMasimo Freedom Medical Smartwatch is Masimo's medical-grade consumer wearable targeting the premium health-tracking market, which grew ~28% YoY and reached $45B globally by end-2025 (IDC, 2025).\u003c\/p\u003e\n\u003cp\u003eUsing Masimo's clinical-grade sensors, the device captured an estimated 12-15% share of premium wearable unit sales in 2025, driving adoption in telehealth pilots and remote patient monitoring.\u003c\/p\u003e\n\u003cp\u003eIt demands heavy R\u0026amp;D and marketing spend-Masimo's Wearables segment cost roughly $120M in capex and opex in 2025-but could shift to a cash cow as subscription telehealth and device-as-a-service revenues scale.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMarket size 2025: $45B, +28% YoY\u003c\/li\u003e\n\u003cli\u003eMasimo premium share: 12-15% (2025)\u003c\/li\u003e\n\u003cli\u003eWearables spend: ~$120M (2025)\u003c\/li\u003e\n\u003cli\u003eUpside: recurring telehealth revenue, device-as-service\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMasimo's high-share, high-growth stars: Iris, SedLine, Radius, O3, Freedom Watch\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMasimo's Stars: Iris, SedLine, Radius VSM\/tetherless, O3 and Freedom Watch-each combines high share (15-30% range) with strong market CAGRs (wireless ~18%, oximetry ~25%, wearables ~28%), driving rapid revenue but needing continued R\u0026amp;D\/sales investment (R\u0026amp;D +18% in 2024; wearables spend ~$120M in 2025).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003eShare\u003c\/th\u003e\n\u003cth\u003eCAGR\u003c\/th\u003e\n\u003cth\u003e2025 Spend\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eIris\u003c\/td\u003e\n\u003ctd\u003e~28%\u003c\/td\u003e\n\u003ctd\u003e~12%\u003c\/td\u003e\n\u003ctd\u003e-\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSedLine\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;30%\u003c\/td\u003e\n\u003ctd\u003e~6%\u003c\/td\u003e\n\u003ctd\u003e-\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRadius\u003c\/td\u003e\n\u003ctd\u003e-\u003c\/td\u003e\n\u003ctd\u003e~18%\u003c\/td\u003e\n\u003ctd\u003e$120M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eO3\u003c\/td\u003e\n\u003ctd\u003e15-20%\u003c\/td\u003e\n\u003ctd\u003e~25%\u003c\/td\u003e\n\u003ctd\u003e-\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFreedom Watch\u003c\/td\u003e\n\u003ctd\u003e12-15%\u003c\/td\u003e\n\u003ctd\u003e~28%\u003c\/td\u003e\n\u003ctd\u003e$120M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eComprehensive BCG Matrix review of Masimo's products with strategic recommendations for investment, retention, or divestment across quadrants.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOne-page Masimo BCG Matrix placing each business unit in a quadrant for quick strategic clarity.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eash Cows\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSET Signal Extraction Technology\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSET Signal Extraction Technology (SET) is the foundation of Masimo's success: as of FY2024 Masimo held an estimated 55-60% global hospital pulse-oximetry market share, keeping SET the industry gold standard.\u003c\/p\u003e\n\u003cp\u003eThis mature tech yields high-margin cash flow-Masimo reported ~45% gross margin on legacy devices in FY2024-and needs low marketing spend thanks to proven motion-accuracy performance.\u003c\/p\u003e\n\u003cp\u003eCash from SET funds R\u0026amp;D and acquisitions in AI and consumer health; in 2024 Masimo generated roughly $1.1B in product revenue from core hospital monitoring, underwriting newer speculative bets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRainbow Pulse CO-Oximetry\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRainbow Pulse CO-Oximetry noninvasively measures hemoglobin and carboxyhemoglobin using Masimo's Rainbow tech, serving a mature pulse-oximetry market valued at about $3.8B in 2024; device+sensor sales generated roughly $620M in Masimo's 2024 revenue, showing high gross margins (~55%) and recurring sensor revenue. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDisposable Adhesive Sensors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe sale of single-use disposable adhesive sensors generates high-volume recurring revenue for Masimo, fitting a classic cash cow: in 2024 Masimo reported device accessory and consumables revenue of about $880 million, driven by an installed base of millions of monitors worldwide.\u003c\/p\u003e\n\u003cp\u003eDemand for these sensors is stable and predictable across cycles; consumables margins exceed device margins, producing steady cash flow that in 2024 helped cover interest on Masimo's net debt (about $1.2 billion end-2024) and fund R\u0026amp;D for next-gen monitoring. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient SafetyNet Surveillance System\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003ePatient SafetyNet is a mature supplemental clinical surveillance system with ~40-50% market share in large US hospital networks as of 2025, driving steady software licensing and maintenance revenue-estimated annual recurring revenue (ARR) contribution of $120-160M to Masimo in FY2024.\u003c\/p\u003e\n\u003cp\u003eWith high customer retention (~90%+ multi-year contracts) and low churn, Masimo milks this cash cow by prioritizing service continuity and incremental upgrades rather than heavy R\u0026amp;D, keeping margins strong in a saturated hospital-wide surveillance market.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMarket share: ~40-50% in US large hospitals (2025)\u003c\/li\u003e\n\u003cli\u003eARR contribution: $120-160M (FY2024 est.)\u003c\/li\u003e\n\u003cli\u003eCustomer retention: ~90%+ on multi-year contracts\u003c\/li\u003e\n\u003cli\u003eStrategy: milking gains via maintenance, SaaS licensing, minor upgrades\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNomoLine Capnography and Gas Monitoring\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eNomoLine sampling lines and Masimo capnography devices hold leading share in respiratory monitoring-estimated market share ~25% in mainstream capnography as of 2025-operating in a mature clinical market with steady low-single-digit annual growth (~3-5% CAGR 2023-2028).\u003c\/p\u003e\n\u003cp\u003eHigh-margin disposable consumables (gross margins often \u0026gt;60% on sampling lines) provide predictable recurring revenue and cash flow, funding Masimo's higher-growth segments like consumer wearables and next-gen sensors.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMarket share ~25% (2025)\u003c\/li\u003e\n\u003cli\u003eSegment CAGR ~3-5% (2023-2028)\u003c\/li\u003e\n\u003cli\u003eGross margin on consumables \u0026gt;60%\u003c\/li\u003e\n\u003cli\u003eStable recurring revenue funds growth initiatives\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMasimo's $2.6B recurring cash engine funds R\u0026amp;D, acquisitions despite $1.2B net debt\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMasimo's cash cows-SET pulse oximetry, Rainbow CO-oximetry, disposable sensors, Patient SafetyNet, and capnography consumables-generated steady, high-margin recurring cash in FY2024-2025 (core product revenue ~$1.1B; consumables ~$880M; Rainbow ~$620M; gross margins 45-60%; ARR PSN $120-160M; net debt ~$1.2B), funding R\u0026amp;D and acquisitions.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eItem\u003c\/th\u003e\n\u003cth\u003eFY2024-25\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCore product rev\u003c\/td\u003e\n\u003ctd\u003e$1.1B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eConsumables\u003c\/td\u003e\n\u003ctd\u003e$880M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRainbow\u003c\/td\u003e\n\u003ctd\u003e$620M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross margins\u003c\/td\u003e\n\u003ctd\u003e45-60%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eARR PSN\u003c\/td\u003e\n\u003ctd\u003e$120-160M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet debt\u003c\/td\u003e\n\u003ctd\u003e$1.2B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eMasimo BCG Matrix\u003c\/h2\u003e\n\u003cp\u003eThe file you're previewing is the exact Masimo BCG Matrix report you'll receive after purchase-no watermarks, no demo placeholders-just a fully formatted, analysis-ready document crafted for strategic clarity and professional presentation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eD\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eogs\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLegacy Consumer Audio Brands\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFollowing Masimo's 2023-2025 strategic pivot and activist investor pressure, the legacy consumer audio brands bought from Sound United are now dogs: they sit in a low-growth (\u0026lt;2% CAGR) retail segment with ~5-8% gross margins and intense price competition, offering little synergy with Masimo's medical device mission.\u003c\/p\u003e\n\u003cp\u003eMasimo prioritizes divestiture or spin-off to stop cash drains-these units generated roughly $150-200M revenue in 2024 but produced operating losses and tied up working capital, so management aims sale\/IPO by H1 2026 to redeploy capital to core medtech.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNon-Medical Consumer Headphones\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNon-medical consumer headphones sit in Masimo's BCG Dogs quadrant: legacy audio units hold \u0026lt;1% market share versus Apple\/Samsung and face ~2% CAGR in mature markets, per 2024 IDC data; projected revenue under $10M FY2025. Turning them around needs high marketing and R\u0026amp;D spend, with expected margins below clinical med-tech (30%+), so phase‑out to reallocate ~$5-15M capex toward clinical devices is recommended.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Hi-Fi Audio Components\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe high-end home audio components business sits in a niche, low-growth segment-global high-fidelity electronics fell 2.8% CAGR 2019-2024 and represented \u0026lt;1% of Masimo's FY2024 $1.6B product revenue-making it a Dog in the BCG matrix.\u003c\/p\u003e\n\u003cp\u003eThese lines hold negligible market share vs consumer electronics leaders and add little strategic value; continuing them ties up management and roughly $8-12M annual OPEX that could fund core healthcare R\u0026amp;D instead.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStandalone Legacy Patient Monitors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eStandalone legacy patient monitors-older, non-connected units-are seeing accelerating decline as hospitals shift to platform-based, software-defined systems like Masimo Iris and Root; market share fell roughly 12% year-over-year in 2024 while integrated platforms grew double digits.\u003c\/p\u003e\n\u003cp\u003eThese legacy devices are low-growth, near break-even SKUs being phased out; capital spending trends show hospital purchases favoring interoperable platforms, cutting legacy unit orders by ~30% between 2022-2024.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLow growth: -12% YoY (2024)\u003c\/li\u003e\n\u003cli\u003eOrders down ~30% (2022-2024)\u003c\/li\u003e\n\u003cli\u003eMostly break-even financially\u003c\/li\u003e\n\u003cli\u003eBeing replaced by Iris and Root platforms\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eThird-Party Distribution of Low-Margin Hardware\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThird-party distribution of low-margin medical hardware that skips Masimo's proprietary sensors yields thin gross margins (often \u0026lt;10%) and negligible market share versus core products; in 2024 Masimo reported device revenue concentration with proprietary sensors driving \u0026gt;70% of device gross profit.\u003c\/p\u003e\n\u003cp\u003eThese distributive activities add no sustainable competitive advantage, diverting resources from high-margin R\u0026amp;D where Masimo's IP generated ~60-70% EBITDA contribution in FY2024; trimming them raises ROI on innovation spend.\u003c\/p\u003e\n\u003cp\u003eReducing third-party distribution can boost operational efficiency, cut SG\u0026amp;A drag (Masimo's FY2024 SG\u0026amp;A was ~28% of revenue), and refocus capital on sensor\/IP development that delivered majority of 2024 device-level margins.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLow-margin hardware: gross margins \u0026lt;10%\u003c\/li\u003e\n\u003cli\u003eCore IP drives \u0026gt;70% device gross profit (2024)\u003c\/li\u003e\n\u003cli\u003eR\u0026amp;D\/innovation produced ~60-70% EBITDA contribution (FY2024)\u003c\/li\u003e\n\u003cli\u003eSG\u0026amp;A was ~28% of revenue (FY2024); trimming lowers overhead\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMasimo to divest low-margin audio devices-$150-200M dogs, capex reallocated to medtech\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMasimo's non-core consumer audio and legacy low-margin devices are BCG Dogs: low growth (\u0026lt;2% CAGR), thin gross margins (5-10%), and ~ $150-200M revenue in 2024 with operating losses; management targets divestiture by H1 2026 to redeploy $5-15M capex to core medtech.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eItem\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e$150-200M\u003c\/td\u003e\n\u003ctd\u003eOperating losses\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross margin\u003c\/td\u003e\n\u003ctd\u003e5-10%\u003c\/td\u003e\n\u003ctd\u003eLow\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGrowth\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;2% CAGR\u003c\/td\u003e\n\u003ctd\u003eDeclining\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCapex reallocate\u003c\/td\u003e\n\u003ctd\u003e$5-15M\u003c\/td\u003e\n\u003ctd\u003eTo core R\u0026amp;D\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eQ\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003euestion Marks\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTelehealth and Remote Patient Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMasimo's telehealth and remote patient management sit in a high-growth market projected at 20% CAGR to 2028, yet Masimo holds a single-digit share versus incumbents like Teladoc; revenue from these platforms was under $100M in FY2024 while R\u0026amp;D and go-to-market spend rose ~25% year-over-year, so they consume cash currently.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStarlight Non-Invasive Glucose Monitoring\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eStarlight non-invasive glucose monitoring is a high-risk, high-reward question mark: global diabetes device market was $24.1B in 2024 and forecasted to reach $37.5B by 2030 (CAGR ~7.8%), so success would be huge.\u003c\/p\u003e\n\u003cp\u003eMasimo has strong optical and signal-processing IP but currently near-zero market share as Starlight is in clinical validation and faces FDA\/CE regulatory hurdles, delaying revenue recognition.\u003c\/p\u003e\n\u003cp\u003eThis classic question mark needs heavy R\u0026amp;D and clinical spend-expect tens to low hundreds of millions of dollars over 2-5 years-to test if it can scale to leader status.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHalo AI Predictive Analytics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe Halo AI Predictive Analytics targets early patient deterioration detection, a high-growth frontier: global AI in healthcare market reached $18.3B in 2024 and is forecast to hit $72.5B by 2030 (CAGR ~25%), so Halo sits in a Question Mark role for Masimo.\u003c\/p\u003e\n\u003cp\u003eMarket share is fragmented-top clinical AI vendors each hold \u0026lt;5-10%-and Masimo must define the category; Halo needs rapid commercial adoption and registrational-grade evidence to scale.\u003c\/p\u003e\n\u003cp\u003eIf Halo fails to show stronger clinical outcomes and ARR growth (SaaS peers scale ARR 40-80% YoY), it risks becoming a Dog in the competitive SaaS-heavy clinical decision support space.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStork Baby Monitoring System\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eStork Baby Monitoring is a Question Mark in Masimo's BCG matrix: it applies Masimo's clinical-grade sensors to the fast-growing smart-nursery market (projected CAGR ~20% to reach $2.5B by 2025), but Masimo holds low consumer share versus incumbents like Owlet and Nanit.\u003c\/p\u003e\n\u003cp\u003eManagement must choose heavy consumer marketing (likely $50-100M+ over 2 years to scale awareness) or re-anchor the tech to clinical use where Masimo's brand and margins are stronger.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMarket size ~ $2.5B by 2025; CAGR ~20%\u003c\/li\u003e\n\u003cli\u003eConsumer share: Masimo small vs leaders Owlet\/Nanit\u003c\/li\u003e\n\u003cli\u003eEstimated consumer-scale marketing: $50-100M over 2 years\u003c\/li\u003e\n\u003cli\u003eClinical pivot leverages existing margins and channel strength\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOpioid Safety Monitoring Solutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eMasimo's opioid safety monitoring solutions sit in Question Marks: the opioid crisis keeps market growth high-US opioid-related ED visits rose ~4% in 2023 to ~3.3M, and home monitoring demand grew ~12% CAGR 2020-2024-yet Masimo's late entry yields low share while facing FDA, CMS, and payer hurdles.\u003c\/p\u003e\n\u003cp\u003eThese products are a strategic gamble: with $4-6B addressable US monitoring market estimates (2025) they could become Stars if adoption and reimbursement scale, or be sold if uptake stays slow.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh market growth: ~12% home monitor CAGR 2020-2024\u003c\/li\u003e\n\u003cli\u003eLow Masimo share: early-stage product line\u003c\/li\u003e\n\u003cli\u003eRegulatory\/reimbursement risk: FDA\/CMS hurdles\u003c\/li\u003e\n\u003cli\u003eAddressable market: $4-6B US (2025 est.)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMasimo's moonshots need $50-200M each to chase huge markets or face divestiture\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMasimo's Question Marks (telehealth, Starlight, Halo, Stork, opioid monitors) sit in high-growth markets (telehealth 20% CAGR to 2028; AI in healthcare $18.3B 2024 → $72.5B 2030; diabetes devices $24.1B 2024), yet Masimo holds low share, FY2024 platform revenue \u0026lt; $100M, R\u0026amp;D +25% YoY; requires $50-200M+ investment per program to prove scale or divest.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003eMarket 2024\u003c\/th\u003e\n\u003cth\u003eMasimo FY2024\u003c\/th\u003e\n\u003cth\u003eInvest 2-5y\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTelehealth\u003c\/td\u003e\n\u003ctd\u003e20% CAGR\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;$100M\u003c\/td\u003e\n\u003ctd\u003e$50-150M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStarlight\u003c\/td\u003e\n\u003ctd\u003e$24.1B diabetes\u003c\/td\u003e\n\u003ctd\u003e~0\u003c\/td\u003e\n\u003ctd\u003e$50-200M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHalo\u003c\/td\u003e\n\u003ctd\u003e$18.3B AI\u003c\/td\u003e\n\u003ctd\u003e~0\u003c\/td\u003e\n\u003ctd\u003e$50-150M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStork\u003c\/td\u003e\n\u003ctd\u003e$2.5B by 2025\u003c\/td\u003e\n\u003ctd\u003e~0\u003c\/td\u003e\n\u003ctd\u003e$50-100M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOpioid\u003c\/td\u003e\n\u003ctd\u003e$4-6B US est.\u003c\/td\u003e\n\u003ctd\u003e~0\u003c\/td\u003e\n\u003ctd\u003e$50-150M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"Ansoff Matrix","offers":[{"title":"Default Title","offer_id":53847618486613,"sku":"masimo-bcg-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1047\/6496\/5205\/files\/masimo-bcg-matrix.webp?v=1778329831","url":"https:\/\/ansoff-matrix.com\/products\/masimo-bcg-matrix","provider":"Ansoff Matrix","version":"1.0","type":"link"}